Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Retrospective Cohort Study
100%
Prognostic Biomarker
100%
Anaplastic Lymphoma Kinase
100%
CYFRA 21-1
100%
CYFRA
100%
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer (ALK-positive NSCLC)
100%
Overall Survival
31%
Progression-free Survival
25%
Non-small Cell Lung Cancer (NSCLC)
18%
Confidence Interval
18%
Hazard Ratio
18%
Carcinoembryonic Antigen
18%
Carcinoembryonic Antigen Levels
18%
Objective Response Rate
12%
Japan
6%
No Significant Difference
6%
Multivariate Analysis
6%
Risk Stratification
6%
Prognostic Factors
6%
Commercially Available
6%
Complete Response Rate
6%
Response Rate
6%
Poor Outcome
6%
Predictive Value
6%
Tumor Progression
6%
Tumor Marker
6%
Cox Regression Model
6%
Response Evaluation Criteria in Solid Tumors (RECIST)
6%
Immunoassay
6%
Risk Treatment
6%
Tumor Resistance
6%
Resistance to Cell Death
6%
ALK Inhibitor
6%
Survival Response
6%
Treatment Planning
6%
Tumor Heterogeneity
6%
Response-outcome
6%
Poorly Differentiated Squamous Cell Carcinoma
6%
Suboptimal Response
6%
Institutional Protocol
6%
Anaplastic Lymphoma Kinase Fusion
6%
TKI Therapy
6%
Non-oncogene Addiction
6%
Median Progression-free Survival
6%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
6%
Elevated Levels
6%
Multivariate Cox Regression
6%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Biological Marker
100%
Retrospective Cohort Study
100%
Anaplastic Lymphoma Kinase
100%
Cytokeratin 19 Fragment
100%
Carcinoembryonic Antigen
42%
Overall Survival
35%
Progression Free Survival
35%
Hazard Ratio
21%
Risk Stratification
7%
Squamous Cell Carcinoma
7%
Tumor Progression
7%
Cell Death
7%
Prognostic Factor
7%
Epidermal Growth Factor Receptor
7%
Retrospective Study
7%
Tumor Marker
7%
Immunoassay
7%
Fusion Gene
7%
Tyrosine-Kinase Inhibitor
7%
Tumor Resistance
7%
Treatment Planning
7%
Tumour Heterogeneity
7%
Response Evaluation Criteria in Solid Tumors
7%
Oncogene Addiction
7%
Cox Regression Model
7%
Multivariate Analysis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Cohort Study
100%
Non Small Cell Lung Cancer
100%
Anaplastic Lymphoma Kinase
100%
Cytokeratin 19 Fragment
100%
Carcinoembryonic Antigen
42%
Overall Survival
35%
Progression Free Survival
35%
Neoplasm
7%
Squamous Cell Carcinoma
7%
Tumor Growth
7%
Solid Malignant Neoplasm
7%
Protein Tyrosine Kinase Inhibitor
7%
Epidermal Growth Factor Receptor
7%
Tumor Marker
7%
Immunoassay
7%
Retrospective Study
7%
Tumor Resistance
7%
Oncogene Addiction
7%
Biochemistry, Genetics and Molecular Biology
Cohort Study
100%
Anaplastic Lymphoma Kinase
100%
Prognostic Biomarker
100%
Carcinoembryonic Antigen
42%
Overall Survival
35%
Progression Free Survival
35%
Oncogene
7%
Tumor Progression
7%
Multivariate Analysis
7%
Immunoassay
7%
Cell Death
7%
Tumor Marker
7%
Epidermal Growth Factor Receptor
7%
Tyrosine Kinase Inhibitor
7%
Fusion Gene
7%
Retrospective Study
7%
Keratin 19
7%